Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014)
- 22 November 2024
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 214, 115144
Abstract
No abstract availableFunding Information
- Dutch Cancer Society
- Roche Netherlands BV
This publication has 4 references indexed in Scilit:
- Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Journal of Clinical Oncology, 2020
- Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trialBritish Journal of Haematology, 2015
- Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trialHaematologica, 2015
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006